Ardaman Shergill to Disease-Free Survival
This is a "connection" page, showing publications Ardaman Shergill has written about Disease-Free Survival.
Connection Strength
0.262
-
Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
Score: 0.049
-
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). J Natl Cancer Inst. 2025 Dec 01; 117(12):2643-2652.
Score: 0.048
-
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. BMC Cancer. 2024 Jul 26; 24(1):901.
Score: 0.043
-
Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol. 2024 08 20; 42(24):2853-2859.
Score: 0.043
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 07 27; 389(4):322-334.
Score: 0.040
-
Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer. JAMA Oncol. 2023 03 01; 9(3):404-413.
Score: 0.039